Incyte Corporation (INCY) 80.81 $INCY
Covered Call reports for Twitter, Incyte Corp., Chico's FAS Inc., SolarCity and Bristol-Myers Squibb include trade ideas that offer returns of 20% or more!
PR Newswire - Thu Sep 01, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for BMY, CHS, INCY, SCTY, and TWTR.
SCTY: 18.78 (-1.88), INCY: 80.81 (-0.29), BMY: 56.76 (-0.63), TWTR: 19.50 (+0.29), CHS: 12.35 (-0.33)
CTI BioPharma Reports Mixed Pacritinib Study Data, Stock Up
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 9:05AM CDT
CTI BioPharma (CTIC) announced top-line results from a phase III study (PERSIST-2) on pacritinib for the treatment of myelofibrosis.
ANIP: 61.42 (+1.68), INCY: 80.81 (-0.29), CTIC: 0.39 (unch), ANIK: 47.94 (+0.70)
Incyte to Present at Upcoming Investor Conferences
BusinessWire - Tue Aug 30, 7:00AM CDT
Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of September:
INCY: 80.81 (-0.29), MS: 31.91 (-0.15)
Forbes Magazine Names Incyte to its List of World's Most Innovative Companies for Second Consecutive Year
BusinessWire - Thu Aug 25, 6:30AM CDT
Incyte Corporation (Nasdaq:INCY) today announced it has been ranked 4th on Forbes magazine's 2016 list of the World's Most Innovative Companies. Incyte, a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, is advancing an innovative and diverse portfolio of large and small molecules comprised of 14 development candidates against 11 different molecular targets.
INCY: 80.81 (-0.29)
Immunovaccine Announces Additional Positive Topline Results from Phase 1/1b Clinical Trial Program With DPX-Survivac in Ovarian Cancer
Marketwired - Thu Aug 25, 6:05AM CDT
Data Reinforces Favorable Safety Profile, Robust Immunogenicity of Company's Lead Cancer Therapy Candidate, and Highlights Optimal Dosing Schedule
IMV.TO: 0.77 (+0.02), INCY: 80.81 (-0.29)
After Yesterday's Rally of 6.97% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Aug 22, 12:25PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $79.11 to a high of $84.39. Yesterday, the shares gained 7.0%, which took the trading range above the 3-day high of $78.56 on volume of 1.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
INCY: 80.81 (-0.29)
Watch for Incyte to Potentially Pullback After Gaining 6.97% Yesterday
Comtex SmarTrend(R) - Mon Aug 22, 12:23PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $79.11 to a high of $84.39. Yesterday, the shares gained 7.0%, which took the trading range above the 3-day high of $78.56 on volume of 1.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
INCY: 80.81 (-0.29)
Incyte Set to Possibly Rebound After Yesterday's Selloff of 2.82%
Comtex SmarTrend(R) - Tue Aug 16, 2:54PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $77.90 to a high of $80.59. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $80.49 on volume of 595,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
INCY: 80.81 (-0.29)
SmarTrend Watching for Potential Rebound in Shares of Incyte After 2.82% Loss
Comtex SmarTrend(R) - Tue Aug 16, 2:53PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $77.90 to a high of $80.59. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $80.49 on volume of 595,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
INCY: 80.81 (-0.29)
Biotech Stocks Technical Report -- Incyte, BioDelivery Sciences Intl., Synthetic Biologics, and Raptor Pharma
PR Newswire - Tue Aug 16, 7:10AM CDT
Stock-Callers.com today has under its microscope the Biotech industry which has stabilized in the second quarter of this year. As per NASDAQ, the segment's overall performance was mixed during Q2 2016 due to the Brexit and the Fed's decision to put off rate hikes. Let us take a closer look at the following equities and see what investors make of them: Incyte Corp. (NASDAQ: INCY), BioDelivery Sciences International Inc. (NASDAQ: BDSI), Synthetic Biologics Inc. (NYSE MKT: SYN), and Raptor Pharmaceuticals Corp. (NASDAQ: RPTP). Today's research reports on the aforementioned stocks are downloadable for free upon registration at:
BDSI: 2.45 (+0.01), SYN: 1.59 (-0.05), RPTP: 7.24 (-0.21), INCY: 80.81 (-0.29)
New Strong Buy Stocks for August 10th
Zacks Equity Research - Zacks Investment Research - Wed Aug 10, 6:42AM CDT
New Strong Buy Stocks for August 10th
NGL: 18.01 (-0.13), CIM: 16.46 (-0.03), INCY: 80.81 (-0.29), GALE: 0.39 (-0.01), ACXM: 26.21 (+0.22)
Repros (RPRX) Q2 Loss Narrower Y/Y, Focus on Pipeline
Arpita Dutt - Zacks Investment Research - Wed Aug 10, 6:38AM CDT
Considering that Repros (RPRX) has no approved product in its portfolio at the moment, investor focus will remain on pipeline updates and cash burn.
CBM: 43.17 (+0.34), GERN: 2.73 (+0.04), INCY: 80.81 (-0.29), RPRX: 2.00 (-0.03)
Incyte Reports 2016 Second-Quarter Financial Results and Updates Key Clinical Programs
BusinessWire - Tue Aug 09, 6:00AM CDT
--ECHO-301, the first Phase 3 trial evaluating epacadostat, now underway in combination with pembrolizumab as first-line treatment of patients with advanced or metastatic melanoma
INCY: 80.81 (-0.29)
Incyte Falls 2.22% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Mon Aug 08, 4:04PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $88.23 to a high of $91.60. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $88.66 on volume of 395,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
INCY: 80.81 (-0.29)
Watch for Incyte to Potentially Rebound After Falling 2.22% Yesterday
Comtex SmarTrend(R) - Mon Aug 08, 4:02PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $88.23 to a high of $91.60. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $88.66 on volume of 395,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
INCY: 80.81 (-0.29)
Drug Stocks to Watch for Earnings on Aug 9: MYL, INCY & More
Zacks Equity Research - Zacks Investment Research - Mon Aug 08, 9:05AM CDT
Will drug stocks Mylan, Incyte and Genmab be able to pull a surprise when they report Q2 results on Aug 9?
JNJ: 119.08 (-0.26), INCY: 80.81 (-0.29), MYL: 41.92 (-0.44), NVS: 78.27 (-0.50)
Mylan (MYL) Q2 Earnings: Will the Stock Disappoint?
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 3:15PM CDT
Mylan (MYL), which is set to report second-quarter 2016 results on Aug 9, delivered a positive earnings surprise of 1.33% last quarter.
IPXL: 23.94 (-0.25), INCY: 80.81 (-0.29), MYL: 41.92 (-0.44), IONS: 30.04 (+0.39)
Can TransDigm (TDG) Spring a Surprise in Q3 Earnings?
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 7:56AM CDT
TransDigm Group Incorporated (TDG) is set to report third-quarter fiscal 2016 results, after the closing bell on Aug 9.
INCY: 80.81 (-0.29), TDG: 287.41 (+2.22), MYL: 41.92 (-0.44), AGI: 7.42 (+0.40)
What's in Store for Myriad Genetics (MYGN) in Q4 Earnings?
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 7:43AM CDT
Myriad's (MYGN) earnings outpaced the Zacks Consensus Estimate in all the past four quarters, with an average beat of 8.70%.
MYGN: 20.44 (+0.08), MDT: 86.98 (-0.05), INCY: 80.81 (-0.29), IONS: 30.04 (+0.39)
Covered Call reports for Twitter, Incyte Corp., Chico's FAS Inc., SolarCity and Bristol-Myers Squibb include trade ideas that offer returns of 20% or more!
PR Newswire - Thu Sep 01, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for BMY, CHS, INCY, SCTY, and TWTR.
SCTY: 18.78 (-1.88), INCY: 80.81 (-0.29), BMY: 56.76 (-0.63), TWTR: 19.50 (+0.29), CHS: 12.35 (-0.33)
CTI BioPharma Reports Mixed Pacritinib Study Data, Stock Up
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 9:05AM CDT
CTI BioPharma (CTIC) announced top-line results from a phase III study (PERSIST-2) on pacritinib for the treatment of myelofibrosis.
ANIP: 61.42 (+1.68), INCY: 80.81 (-0.29), CTIC: 0.39 (unch), ANIK: 47.94 (+0.70)
Incyte to Present at Upcoming Investor Conferences
BusinessWire - Tue Aug 30, 7:00AM CDT
Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of September:
INCY: 80.81 (-0.29), MS: 31.91 (-0.15)
Forbes Magazine Names Incyte to its List of World's Most Innovative Companies for Second Consecutive Year
BusinessWire - Thu Aug 25, 6:30AM CDT
Incyte Corporation (Nasdaq:INCY) today announced it has been ranked 4th on Forbes magazine's 2016 list of the World's Most Innovative Companies. Incyte, a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, is advancing an innovative and diverse portfolio of large and small molecules comprised of 14 development candidates against 11 different molecular targets.
INCY: 80.81 (-0.29)
Immunovaccine Announces Additional Positive Topline Results from Phase 1/1b Clinical Trial Program With DPX-Survivac in Ovarian Cancer
Marketwired - Thu Aug 25, 6:05AM CDT
Data Reinforces Favorable Safety Profile, Robust Immunogenicity of Company's Lead Cancer Therapy Candidate, and Highlights Optimal Dosing Schedule
IMV.TO: 0.77 (+0.02), INCY: 80.81 (-0.29)
After Yesterday's Rally of 6.97% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Aug 22, 12:25PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $79.11 to a high of $84.39. Yesterday, the shares gained 7.0%, which took the trading range above the 3-day high of $78.56 on volume of 1.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
INCY: 80.81 (-0.29)
Watch for Incyte to Potentially Pullback After Gaining 6.97% Yesterday
Comtex SmarTrend(R) - Mon Aug 22, 12:23PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $79.11 to a high of $84.39. Yesterday, the shares gained 7.0%, which took the trading range above the 3-day high of $78.56 on volume of 1.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
INCY: 80.81 (-0.29)
Incyte Set to Possibly Rebound After Yesterday's Selloff of 2.82%
Comtex SmarTrend(R) - Tue Aug 16, 2:54PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $77.90 to a high of $80.59. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $80.49 on volume of 595,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
INCY: 80.81 (-0.29)
SmarTrend Watching for Potential Rebound in Shares of Incyte After 2.82% Loss
Comtex SmarTrend(R) - Tue Aug 16, 2:53PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $77.90 to a high of $80.59. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $80.49 on volume of 595,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
INCY: 80.81 (-0.29)
Biotech Stocks Technical Report -- Incyte, BioDelivery Sciences Intl., Synthetic Biologics, and Raptor Pharma
PR Newswire - Tue Aug 16, 7:10AM CDT
Stock-Callers.com today has under its microscope the Biotech industry which has stabilized in the second quarter of this year. As per NASDAQ, the segment's overall performance was mixed during Q2 2016 due to the Brexit and the Fed's decision to put off rate hikes. Let us take a closer look at the following equities and see what investors make of them: Incyte Corp. (NASDAQ: INCY), BioDelivery Sciences International Inc. (NASDAQ: BDSI), Synthetic Biologics Inc. (NYSE MKT: SYN), and Raptor Pharmaceuticals Corp. (NASDAQ: RPTP). Today's research reports on the aforementioned stocks are downloadable for free upon registration at:
BDSI: 2.45 (+0.01), SYN: 1.59 (-0.05), RPTP: 7.24 (-0.21), INCY: 80.81 (-0.29)
New Strong Buy Stocks for August 10th
Zacks Equity Research - Zacks Investment Research - Wed Aug 10, 6:42AM CDT
New Strong Buy Stocks for August 10th
NGL: 18.01 (-0.13), CIM: 16.46 (-0.03), INCY: 80.81 (-0.29), GALE: 0.39 (-0.01), ACXM: 26.21 (+0.22)
Repros (RPRX) Q2 Loss Narrower Y/Y, Focus on Pipeline
Arpita Dutt - Zacks Investment Research - Wed Aug 10, 6:38AM CDT
Considering that Repros (RPRX) has no approved product in its portfolio at the moment, investor focus will remain on pipeline updates and cash burn.
CBM: 43.17 (+0.34), GERN: 2.73 (+0.04), INCY: 80.81 (-0.29), RPRX: 2.00 (-0.03)
Incyte Reports 2016 Second-Quarter Financial Results and Updates Key Clinical Programs
BusinessWire - Tue Aug 09, 6:00AM CDT
--ECHO-301, the first Phase 3 trial evaluating epacadostat, now underway in combination with pembrolizumab as first-line treatment of patients with advanced or metastatic melanoma
INCY: 80.81 (-0.29)
Incyte Falls 2.22% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Mon Aug 08, 4:04PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $88.23 to a high of $91.60. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $88.66 on volume of 395,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
INCY: 80.81 (-0.29)
Watch for Incyte to Potentially Rebound After Falling 2.22% Yesterday
Comtex SmarTrend(R) - Mon Aug 08, 4:02PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $88.23 to a high of $91.60. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $88.66 on volume of 395,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
INCY: 80.81 (-0.29)
Drug Stocks to Watch for Earnings on Aug 9: MYL, INCY & More
Zacks Equity Research - Zacks Investment Research - Mon Aug 08, 9:05AM CDT
Will drug stocks Mylan, Incyte and Genmab be able to pull a surprise when they report Q2 results on Aug 9?
JNJ: 119.08 (-0.26), INCY: 80.81 (-0.29), MYL: 41.92 (-0.44), NVS: 78.27 (-0.50)
Mylan (MYL) Q2 Earnings: Will the Stock Disappoint?
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 3:15PM CDT
Mylan (MYL), which is set to report second-quarter 2016 results on Aug 9, delivered a positive earnings surprise of 1.33% last quarter.
IPXL: 23.94 (-0.25), INCY: 80.81 (-0.29), MYL: 41.92 (-0.44), IONS: 30.04 (+0.39)
Can TransDigm (TDG) Spring a Surprise in Q3 Earnings?
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 7:56AM CDT
TransDigm Group Incorporated (TDG) is set to report third-quarter fiscal 2016 results, after the closing bell on Aug 9.
INCY: 80.81 (-0.29), TDG: 287.41 (+2.22), MYL: 41.92 (-0.44), AGI: 7.42 (+0.40)
What's in Store for Myriad Genetics (MYGN) in Q4 Earnings?
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 7:43AM CDT
Myriad's (MYGN) earnings outpaced the Zacks Consensus Estimate in all the past four quarters, with an average beat of 8.70%.
MYGN: 20.44 (+0.08), MDT: 86.98 (-0.05), INCY: 80.81 (-0.29), IONS: 30.04 (+0.39)
